Freeze-dried amlodipine besylate orally disintegrating tablet and preparation method thereof
By using maltodextrin and gum acacia as skeleton support and suspension in amlodipine benzenesulfonate lyophilized oral disintegration tablets, the problem of tablets being prone to agglomeration and poor moldability is solved, and better stability is achieved Sex and ease of taking.
Patent Information
- Application Number
- CN202111254686.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-10-27
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-10-27
AI Technical Summary
Existing oral disintegrating tablets with amlodipine benzenesulfonate are prone to cause agglomeration and poor moldability, resulting in poor tablet stability and moldability.
Maltodextrin is used as the skeleton support agent and gum acacia as suspending agent, combined with an appropriate amount of binder and sweetener, to ensure uniform mixing of raw materials and tablet forming through a specific lyophilization preparation process.
It effectively avoids the aggregation and agglomeration of main drugs and excipients, improves the moldability and stability of the tablets, and ensures the uniformity of freeze-dried oral disintegration tablets and the convenience of taking them.
Smart Images

Figure CN116019773B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of oral preparations, and in particular to a freeze-dried amlodipine besylate orally disintegrating tablet and a preparation method thereof. Background Art
[0002] With the improvement of people's living standards and changes in dietary structure and lifestyle, the incidence of hypertension has gradually increased in recent years. Hypertension can cause damage to the heart, brain, kidney and other organs of patients, and is closely related to sugar and lipid metabolism disorders and diabetes, significantly reducing the quality of life of patients, and even endangering their lives in severe cases. Therefore, the research on drugs for the treatment of hypertension has attracted more and more attention from scholars at home and abroad.
[0003] Amlodipine besylate is a commonly used drug for the treatment of hypertension and angina pectoris. It is a calcium ion antagonist that acts directly on vascular smooth muscle to reduce peripheral vascular resistance, thereby lowering blood pressure; it reduces peripheral resistance by dilating peripheral arterioles, thereby reducing myocardial oxygen consumption. In addition, it dilates the coronary arteries and coronary arterioles in normal and ischemic areas, thereby increasing myocardial oxygen supply in patients with coronary artery spasm, thereby achieving the purpose of relieving angina pectoris.
[0004] Compared with other tablet dosage forms, amlodipine besylate is more advantageous in the form of freeze-dried orally disintegrating tablets. It does not need to be taken with water, and saliva can make it quickly disintegrate or dissolve in the mouth; a considerable portion is absorbed through the mouth, reducing the first-pass effect of the liver; the orally disintegrating tablets quickly disintegrate and disperse into fine particles before the drug reaches the gastrointestinal tract, avoiding the problem of excessive gastrointestinal tract stimulation caused by excessive local concentration of the drug in the gastrointestinal tract. However, due to the auxiliary material components and preparation process of the freeze-dried orally disintegrating tablets of amlodipine besylate, the current freeze-dried orally disintegrating tablets of amlodipine besylate are prone to agglomeration, and the tablets are not easy to form and have poor tablet stability.
[0005] In the preparation process of amlodipine besylate freeze-dried orally disintegrating tablets, the main ingredient amlodipine besylate has poor stability, is easy to absorb moisture when wet, and is very sensitive to light and temperature. The electrostatic effect will cause the main ingredient amlodipine besylate and various excipients in the amlodipine besylate freeze-dried orally disintegrating tablets to easily aggregate or adhere to the inner wall of the container. Therefore, the selection of excipients in amlodipine besylate freeze-dried orally disintegrating tablets is very critical.
[0006] Patent CN102525972A discloses a method for preparing an amlodipine besylate orally disintegrating tablet: (a) preparation of a matrix solution: adding amlodipine besylate, glycine or mannitol or a mixture thereof, pullulan or sodium alginate or a mixture thereof, and a sweetener and a fragrance to a solution of fully dissolved xanthan gum or konjac gum or a mixture thereof to form a uniform solution; (b) degassing; (c) injection molding; (d) prefreezing; (e) then transferring the mold into a freeze dryer, and freeze-drying for 1 to 10 hours at a pressure of 0.01 mbar to 10 mbar and a temperature of -30°C to 30°C to obtain an amlodipine besylate orally disintegrating tablet.
[0007] Patent CN1546024A discloses an amlodipine besylate orally disintegrating tablet, the main drug of which is amlodipine besylate, and the auxiliary materials include lactose, mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, sodium bicarbonate, citric acid, aspartame, flavor, and magnesium stearate.
[0008] However, the applicant found that when xanthan gum is selected as a suspending agent and mixed with the main drug amlodipine besylate, the amlodipine besylate freeze-dried orally disintegrating tablets will cause agglomeration; when mannitol or glycine is selected as a skeleton support agent and mixed with the main drug amlodipine besylate, the amlodipine besylate freeze-dried orally disintegrating tablets will cause the tablet forming property of the amlodipine besylate freeze-dried orally disintegrating tablets to deteriorate. Therefore, it is an urgent problem to propose an amlodipine besylate freeze-dried orally disintegrating tablet that can avoid the aggregation of the main drug and the auxiliary materials and thus produce agglomeration and improve the tablet forming problem. Summary of the invention
[0009] The invention overcomes the defects of the prior art that the main drug and the auxiliary materials aggregate to form lumps, the tablets are difficult to form, the drug solution is sticky, the bottom is sticky, the edges are cracked, and the tablets are concave, and provides a prescription and a preparation method of amlodipine besylate freeze-dried oral disintegrating tablets that can ensure uniform mixing of various raw materials, good tablet formability, and excellent stability.
[0010] The first aspect of the present invention provides a freeze-dried orally disintegrating tablet, which contains a pharmaceutically active ingredient, a binder, a skeleton support agent and a suspending agent, wherein the skeleton support agent is maltodextrin and the suspending agent is gum arabic.
[0011] Furthermore, the freeze-dried orally disintegrating tablet also contains a sweetener or an edible flavor or a mixture of a sweetener and an edible flavor.
[0012] Furthermore, the active pharmaceutical ingredient in the freeze-dried orally disintegrating tablet is selected from: amlodipine or a pharmaceutically acceptable salt or ester thereof, preferably a pharmaceutically acceptable salt of amlodipine.
[0013] Furthermore, the amlodipine or its pharmaceutically acceptable salt or ester in the freeze-dried orally disintegrating tablet is selected from the group consisting of: amlodipine besylate, amlodipine mesylate, amlodipine L-aspartate, amlodipine camphorsulfonate, amlodipine camphorsulfonate, amlodipine nicotinate, amlodipine pyroglutamate, amlodipine gentisate, amlodipine lipoate and amlodipine maleate, or a combination of two or more thereof, preferably amlodipine besylate.
[0014] Furthermore, the freeze-dried orally disintegrating tablet contains 0.01 to 2.0 parts of amlodipine besylate by weight. Preferably, the freeze-dried orally disintegrating tablet contains 0.1 to 1.0 parts of amlodipine besylate (such as 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0) by weight. Particularly preferably, the freeze-dried orally disintegrating tablet contains 0.693 parts of amlodipine besylate by weight.
[0015] Furthermore, the freeze-dried orally disintegrating tablet contains 0.1 to 2.0 parts of a binder by weight. Preferably, the freeze-dried orally disintegrating tablet contains 0.1 to 1.0 parts of a binder (such as 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0) by weight. Particularly preferably, the freeze-dried orally disintegrating tablet contains 0.8 parts of a binder by weight, wherein the binder is selected from: pullulan, alginate, hydroxypropyl methylcellulose, hyaluronic acid, modified starch, polyvinyl alcohol and chitosan, or a combination of more than two thereof. Preferably, the binder is pullulan.
[0016] Furthermore, the freeze-dried orally disintegrating tablet contains 1.0 to 10.0 parts of maltodextrin by weight. Preferably, the freeze-dried orally disintegrating tablet contains 2.0 to 8.0 parts of maltodextrin by weight (such as 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0). Particularly preferably, the freeze-dried orally disintegrating tablet contains 5.0 parts of maltodextrin by weight.
[0017] Furthermore, the freeze-dried orally disintegrating tablet contains 0.01 to 2.0 parts of gum arabic by weight. Preferably, the freeze-dried orally disintegrating tablet contains 0.01 to 1.0 parts of gum arabic by weight (such as 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0). Particularly preferably, the freeze-dried orally disintegrating tablet contains 0.72 parts of gum arabic by weight.
[0018] Furthermore, the freeze-dried orally disintegrating tablet contains 0.01 to 1.0 parts of sweetener by weight. Preferably, the freeze-dried orally disintegrating tablet contains 0.01 to 0.5 parts of sweetener by weight (such as 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5). Particularly preferably, the freeze-dried orally disintegrating tablet contains 0.1 parts of sweetener by weight, wherein the sweetener is selected from: one or a combination of two or more natural or synthetic sweeteners such as sucralose, aspartame, saccharin sodium, neotame, acesulfame potassium, aspartame and sucrose. Preferably, the sweetener is sucralose.
[0019] Furthermore, the freeze-dried orally disintegrating tablet contains 0.01 to 1.0 parts of edible flavors by weight. Preferably, the freeze-dried orally disintegrating tablet contains 0.01 to 0.1 parts of edible flavors by weight (such as 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 1.0). Particularly preferably, the freeze-dried orally disintegrating tablet contains 0.04 parts of edible flavors by weight, wherein the edible flavor is selected from: mint flavor, sweet orange flavor, pineapple flavor, strawberry flavor, or a combination of two or more thereof. Preferably, the edible flavor is mint flavor.
[0020] The freeze-dried oral disintegrating tablets of amlodipine besylate of the present invention are different from the existing prescriptions, which usually adopt glycine or mannitol as a skeleton support agent, and xanthan gum or sodium alginate as a suspending agent, and cannot effectively improve the problems of drug agglomeration, tablets being difficult to form, drug liquid sticking, sticking to the bottom, cracked edges, and concave tablet shapes. The present invention adopts maltodextrin as a skeleton support agent, and gum arabic as a suspending agent, which can ensure that each raw material is uniformly mixed, and then effectively avoids the phenomenon that the electrostatic effect existing due to the poor stability of the main drug amlodipine besylate, which is easy to absorb moisture when wet, and can cause it to easily aggregate with various auxiliary materials and then agglomerate, and the obtained tablet has good formability and excellent stability. Therefore, selecting suitable prescription composition and dosage ratio produces a key impact on the stability and formability of the freeze-dried oral disintegrating tablets of amlodipine besylate.
[0021] In a specific embodiment of the present invention, the freeze-dried orally disintegrating tablet comprises:
[0022] 0.01-2.0 parts of amlodipine besylate;
[0023] Adhesive 0.1-2.0 parts;
[0024] Maltodextrin 1.0-10.0 parts;
[0025] Gum Arabic 0.01-2.0 parts;
[0026] Sweetener 0.01-0.5 parts;
[0027] 0.01-1.0 portion of edible flavor.
[0028] In a specific embodiment of the present invention, the freeze-dried orally disintegrating tablet comprises:
[0029] 0.01-2.0 parts of amlodipine besylate;
[0030] Pullulan 0.1-2.0 parts;
[0031] Maltodextrin 1.0-10.0 parts;
[0032] Gum Arabic 0.01-2.0 parts;
[0033] Sucralose 0.01-0.5 parts;
[0034] Mint essence 0.01-1.0 parts.
[0035] In a specific embodiment of the present invention, the unit dose of the freeze-dried orally disintegrating tablet comprises:
[0036] Amlodipine besylate 6.93 mg;
[0037] Pullulan 8mg;
[0038] Maltodextrin 50mg;
[0039] Gum Arabic 7.2mg;
[0040] Sucralose 1 mg;
[0041] Mint flavor 0.4mg.
[0042] The second aspect of the present invention provides a method for preparing the above-mentioned freeze-dried orally disintegrating tablet, which comprises the following steps:
[0043] (1) Weighing the active ingredient, binder, maltodextrin and gum arabic, adding water, stirring to obtain a lyophilized solution;
[0044] (2) degassing the lyophilized solution in step (1);
[0045] (3) injecting the degassed freeze-dried solution in step (2) into a mold;
[0046] (4) freeze-drying the mold filled with the freeze-dried solution in step (3);
[0047] Furthermore, the pharmaceutically active ingredient in step (1) of the present invention is selected from: amlodipine or a pharmaceutically acceptable salt or ester thereof, preferably a pharmaceutically acceptable salt of amlodipine.
[0048] Furthermore, the amlodipine or its pharmaceutically acceptable salt or ester is selected from the group consisting of: amlodipine besylate, amlodipine mesylate, amlodipine L-aspartate, amlodipine camphorsulfonate, amlodipine camphorsulfonate, amlodipine nicotinate, amlodipine pyroglutamate, amlodipine gentisate, amlodipine lipoic acid and amlodipine maleate, or a combination of two or more thereof, preferably amlodipine besylate.
[0049] Furthermore, the adhesive in step (1) of the present invention is selected from: one or a combination of two or more of pullulan, alginate, hydroxypropyl methylcellulose, hyaluronic acid, modified starch, polyvinyl alcohol and chitosan. Preferably, the adhesive is pullulan.
[0050] Further, the active pharmaceutical ingredient in step (1) of the present invention is a raw material drug that has been pulverized, and the pulverization controls the particle size D90 to be 10 μm; the water addition is divided into two steps, the first step is to add 20% of the prescription amount of purified water at one time, and the second step is to gradually add water to 80% of the prescription amount of purified water; the heating is water bath heating, the water bath heating temperature is 30-50°C, the time is 20-40min, preferably, the water bath heating temperature is 35-45°C, the time is 25-35min, more preferably, the water bath heating temperature is 40°C, the time is 30min; the stirring is homogenous shear stirring, the homogenous shear speed is 2000-8000r / min, the homogenous shear time is 2-15min, preferably, the homogenous shear speed is 2000-4000r / min, the homogenous shear time is 2-10min, more preferably, the homogenous shear speed is 2500r / min, and the homogenous shear time is 30min.
[0051] Furthermore, the degassing treatment in step (2) of the present invention is to transfer the sample solution to a degassing bottle and degas the solution by vacuuming until no bubbles are generated.
[0052] Furthermore, the freeze-drying molding in step (4) of the present invention includes pre-freezing at -40 to -80°C for 3 to 15 minutes, preferably, pre-freezing at -50 to -70°C for 3 to 10 minutes, and more preferably, pre-freezing at -60°C for 5 minutes.
[0053] Furthermore, the freeze-drying molding process in step (4) of the present invention includes: setting the initial freeze-drying temperature to -30°C, placing the pre-frozen blister plate in a freeze drying chamber, setting the cold trap temperature to -40°C to -60°C, and the vacuum degree to 10 to 60 Pa, preferably, the vacuum degree to 20-30 Pa; setting the plate layer temperature: from -30°C to -5°C for 25 minutes; maintaining at -5°C for 120 minutes; and from -5°C to 25°C for 30 minutes.
[0054] The second aspect of the present invention also provides another method for preparing the above-mentioned freeze-dried orally disintegrating tablet, which comprises the following steps:
[0055] (1) Weighing the active ingredient, binder, maltodextrin and gum arabic, adding water, stirring, heating, cooling to room temperature, adding sweetener and edible flavor, stirring, and obtaining a lyophilized solution;
[0056] (2) degassing the lyophilized solution in step (1);
[0057] (3) injecting the degassed freeze-dried solution in step (2) into a mold;
[0058] (4) freeze-drying the mold filled with the freeze-dried solution in step (3).
[0059] Furthermore, the pharmaceutically active ingredient in step (1) of the present invention is selected from: amlodipine or a pharmaceutically acceptable salt or ester thereof, preferably a pharmaceutically acceptable salt of amlodipine.
[0060] Furthermore, the amlodipine or its pharmaceutically acceptable salt or ester is selected from the group consisting of: amlodipine besylate, amlodipine mesylate, amlodipine L-aspartate, amlodipine camphorsulfonate, amlodipine camphorsulfonate, amlodipine nicotinate, amlodipine pyroglutamate, amlodipine gentisate, amlodipine lipoic acid and amlodipine maleate, or a combination of two or more thereof, preferably amlodipine besylate.
[0061] Furthermore, the adhesive in step (1) of the present invention is selected from: one or a combination of two or more of pullulan, alginate, hydroxypropyl methylcellulose, hyaluronic acid, modified starch, polyvinyl alcohol and chitosan. Preferably, the adhesive is pullulan.
[0062] Furthermore, the sweetener described in step (1) of the present invention is selected from: one or a combination of two or more natural or synthetic sweeteners such as sucralose, aspartame, saccharin sodium, neotame, acesulfame potassium, aspartame and sucrose. Preferably, the sweetener is sucralose.
[0063] Furthermore, the edible flavor described in step (1) of the present invention is selected from: mint flavor, sweet orange flavor, pineapple flavor, strawberry flavor, or a combination of two or more thereof. Preferably, the edible flavor is mint flavor.
[0064] Further, the active pharmaceutical ingredient in step (1) of the present invention is a raw material drug that has been pulverized, and the pulverization controls the particle size D90 to be 10 μm; the water addition is divided into two steps, the first step is to add 20% of the prescription amount of purified water at one time, and the second step is to gradually add water to 80% of the prescription amount of purified water; the heating is water bath heating, the water bath heating temperature is 30-50°C, the time is 20-40min, preferably, the water bath heating temperature is 35-45°C, the time is 25-35min, more preferably, the water bath heating temperature is 40°C, the time is 30min; the stirring is homogenous shear stirring, the homogenous shear speed is 2000-8000r / min, the homogenous shear time is 2-15min, preferably, the homogenous shear speed is 2000-4000r / min, the homogenous shear time is 2-10min, more preferably, the homogenous shear speed is 2500r / min, and the homogenous shear time is 30min.
[0065] Furthermore, the degassing treatment in step (2) of the present invention is to transfer the sample solution to a degassing bottle and degas the solution by vacuuming until no bubbles are generated.
[0066] Furthermore, the freeze-drying molding in step (4) of the present invention includes pre-freezing at -40 to -80°C for 3 to 15 minutes, preferably, pre-freezing at -50 to -70°C for 3 to 10 minutes, and more preferably, pre-freezing at -60°C for 5 minutes.
[0067] Furthermore, the freeze-drying molding process in step (4) of the present invention includes: setting the initial freeze-drying temperature to -30°C, placing the pre-frozen blister plate in a freeze drying chamber, setting the cold trap temperature to -40°C to -60°C, and the vacuum degree to 10 to 60 Pa, preferably, the vacuum degree to 20-30 Pa; setting the plate layer temperature: from -30°C to -5°C for 25 minutes; maintaining at -5°C for 120 minutes; and from -5°C to 25°C for 30 minutes.
[0068] In a specific embodiment of the present invention, the method for preparing the freeze-dried orally disintegrating tablet comprises the following steps:
[0069] (1) Weighing amlodipine besylate, pullulan, maltodextrin and gum arabic, adding water, stirring, heating, cooling to room temperature, adding sucralose and mint essence, stirring, and obtaining a lyophilized solution;
[0070] (2) degassing the lyophilized solution in step (1);
[0071] (3) injecting the degassed freeze-dried solution in step (2) into a mold;
[0072] (4) freeze-drying the mold filled with the freeze-dried solution in step (3).
[0073] Further, the amlodipine besylate described in step (1) of the present invention is a raw material drug that has been pulverized, and the pulverization controls the particle size D90 to be 10 μm; the water addition is divided into two steps, the first step is to add 20% of the prescription amount of purified water at one time, and the second step is to gradually add water to 80% of the prescription amount of purified water; the heating is water bath heating, the water bath heating temperature is 30-50° C., the time is 20-40 min, preferably, the water bath heating temperature is 35-45° C., the time is 25-35 min, more preferably, the water bath heating temperature is 40° C., the time is 30 min; the stirring is homogenous shear stirring, the homogenous shear speed is 2000-8000 r / min, the homogenous shear time is 2-15 min, preferably, the homogenous shear speed is 2000-4000 r / min, the homogenous shear time is 2-10 min, more preferably, the homogenous shear speed is 2500 r / min, and the homogenous shear time is 30 min.
[0074] Furthermore, the degassing treatment in step (2) of the present invention is to transfer the sample solution to a degassing bottle and degas the solution by vacuuming until no bubbles are generated.
[0075] Furthermore, the freeze-drying molding in step (4) of the present invention includes pre-freezing at -40 to -80°C for 3 to 15 minutes, preferably, pre-freezing at -50 to -70°C for 3 to 10 minutes, and more preferably, pre-freezing at -60°C for 5 minutes.
[0076] Furthermore, the freeze-drying molding process in step (4) of the present invention includes: setting the initial freeze-drying temperature to -30°C, placing the pre-frozen blister plate in a freeze drying chamber, setting the cold trap temperature to -40°C to -60°C, and the vacuum degree to 10 to 60 Pa, preferably, the vacuum degree to 20-30 Pa; setting the plate layer temperature: from -30°C to -5°C for 25 minutes; maintaining at -5°C for 120 minutes; and from -5°C to 25°C for 30 minutes.
[0077] The present invention improves the formulation and preparation process of amlodipine besylate freeze-dried oral disintegrating tablets. The formulation of the present invention effectively improves the problem of tablet agglomeration caused by the poor stability of the raw material amlodipine besylate and its easy absorption of moisture when wet, ensuring that the tablets have good formability and excellent stability; in the preparation process of the present invention, the raw material amlodipine besylate is crushed and its particle size D90 is controlled to be 10 μm. Compared with other preparation processes, the particle size is significantly reduced, and the raw material amlodipine besylate is dry-mixed with various auxiliary materials and then water is added, and the water is added twice to ensure that the various raw materials can be fully mixed and evenly mixed; the volume of the amlodipine besylate freeze-dried oral disintegrating tablet is small The invention is convenient to take, and does not need to be taken with water, and can be disintegrated or dissolved by saliva, and is especially suitable for the elderly, children, patients with dysphagia and those who have difficulty in getting water; the bioavailability is high, and a considerable part of the drug is absorbed through the mouth, thus avoiding the first-pass effect of the liver; the drug is absorbed quickly in the gastrointestinal tract, and can be quickly disintegrated and dispersed into fine particles before the drug reaches the gastrointestinal tract, resulting in a large area of drug distribution in the gastrointestinal tract, increasing the absorption points, and greatly improving the absorption rate of the drug in the gastrointestinal tract; the freeze-dried oral disintegrating tablets of amlodipine besylate have simple materials, moderate tablet weight, are not easy to break, have a simple preparation process, and are suitable for large-scale industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0078] Figure 1 It is a front view schematic diagram of a freeze-dried orally disintegrating tablet product prepared according to prescription 1, wherein the two tablets on the left and right are both front views of the freeze-dried orally disintegrating tablet product.
[0079] Figure 2 It is a schematic diagram of the back side of the freeze-dried orally disintegrating tablet product prepared according to prescription 1, wherein the two tablets on the left and right are both the back side of the freeze-dried orally disintegrating tablet product.
[0080] Figure 3 This is a front view schematic diagram of a freeze-dried orally disintegrating tablet product prepared according to prescription 2. The two tablets on the left and right are both front views of the freeze-dried orally disintegrating tablet product.
[0081] Figure 4 It is a schematic diagram of the back side of the freeze-dried orally disintegrating tablet product prepared according to prescription 2, wherein the two tablets on the left and right are both the back side of the freeze-dried orally disintegrating tablet product.
[0082] Figure 5 It is a front view schematic diagram of a freeze-dried orally disintegrating tablet product prepared according to prescription 3, wherein the two tablets on the left and right are both front views of the freeze-dried orally disintegrating tablet product.
[0083] Figure 6 It is a schematic diagram of the back side of the freeze-dried orally disintegrating tablet product prepared according to prescription 3, wherein the two tablets on the left and right are both the back side of the freeze-dried orally disintegrating tablet product.
[0084] Figure 7 It is a front view schematic diagram of a freeze-dried orally disintegrating tablet product prepared according to prescription 4, wherein the two tablets on the left and right are both front views of the freeze-dried orally disintegrating tablet product.
[0085] Figure 8 It is a schematic diagram of the back side of the freeze-dried orally disintegrating tablet product of amlodipine besylate prepared according to prescription 4, wherein the two tablets on the left and right are both the back side of the freeze-dried orally disintegrating tablet product.
[0086] Fig. 9 It is a front view schematic diagram of the freeze-dried orally disintegrating tablet product of amlodipine besylate prepared according to prescription 5, wherein the two tablets on the left and right are both front views of the freeze-dried orally disintegrating tablet product.
[0087] Fig.10 This is a schematic diagram of the back of the freeze-dried orally disintegrating tablet product of amlodipine besylate prepared according to prescription 5, wherein the two tablets on the left and right are both back views of the freeze-dried orally disintegrating tablet product. DETAILED DESCRIPTION
[0088] In order to more clearly understand the technical content of the present invention, the following examples are specifically described in detail, the purpose of which is only to better understand the content of the present invention but not to limit the scope of protection of the present invention. The reagents used in the examples of the present invention are all commercially available. The scoring criteria for the freeze-dried orally disintegrating tablets in the examples of the present invention are as follows: 5+ full score, 4+ and above are qualified.
[0089] Example 1 Investigating the effect of using gum arabic as a suspending agent in the prescription on the freeze-dried orally disintegrating tablets of amlodipine besylate
[0090] 1.1 Preparation method of amlodipine besylate freeze-dried orally disintegrating tablets
[0091] The amlodipine besylate freeze-dried orally disintegrating tablets were prepared according to the prescription in the following table.
[0092] (1) Weigh the prescribed amount of maltodextrin, pullulan, gum arabic, and API (grinded to control the particle size D90 to 10 μm) in a 100 ml shear cup, dry mix, add 20% of the prescribed amount of purified water and stir, then gradually add to 80% of the prescribed amount of purified water, bathe in 40°C water for 30 min, cool to room temperature, add the prescribed amount of sucralose and mint essence, and stir to dissolve;
[0093] (2) Volume determination: The sample solutions are respectively determined to the total weight of each prescription;
[0094] (3) Shearing: speed 2500 rpm, time 30 min;
[0095] (4) Degassing: Transfer the sample solution to a degassing bottle and degas by vacuuming until no bubbles are generated;
[0096] (5) Filling and pre-freezing: Use a pipette to inject the sample, with the injection amount of 0.4 g / tablet, and place the injected aluminum-plastic blister in a -60°C low-temperature storage box for pre-freezing;
[0097] (6) Freeze drying: Set the initial freeze drying temperature to -30°C and place the pre-frozen blister plate into the freeze drying chamber. The specific freeze drying setting parameters are as follows:
[0098] Cold trap temperature: -40℃~-60℃; vacuum control: 20~30pa;
[0099] Plate temperature: from -30℃ to -5℃, 25 minutes; maintain -5℃, 120 minutes;
[0100] From -5℃ to 25℃, 30 minutes.
[0101] name effect Prescription 1 API Active ingredients 0.693g Pullulan Adhesives 0.8g Maltodextrin Scaffold Agent 5g Glycine Scaffold Agent / Mannitol Scaffold Agent / Gum Arabic Suspending Agents 720mg Sodium alginate Suspending Agents / Xanthan gum Suspending Agents / Sucralose Flavoring agents 100mg Mint flavor Flavoring agents 40mg Wahaha purified water Solvents / Total weight / 40.0g
[0102] 1.2 Experimental Results
[0103] prescription Prescription 1 Intermediate solution 5+ Appearance 5+ Sticky wall 4+ Disintegration 5+
[0104] Comparative Example 1 Investigating the Effect of Using Sodium Alginate or Xanthan Gum as Suspending Agent on Freeze-dried Orally Disintegrating Tablets of Amlodipine Besylate
[0105] 1.1 Preparation method of amlodipine besylate freeze-dried orally disintegrating tablets
[0106] The amlodipine besylate freeze-dried orally disintegrating tablets were prepared according to the prescription in the following table.
[0107] (1) Weigh the prescribed amount of maltodextrin, pullulan, sodium alginate or xanthan gum, and API (grinded to control the particle size D90 to 10 μm) in a 100 ml shear cup, dry mix, add 20% of the prescribed amount of purified water and stir, then gradually add to 80% of the prescribed amount of purified water, bathe in 40°C water for 30 min, cool to room temperature, add the prescribed amount of sucralose and mint flavor, and stir to dissolve;
[0108] (2) Volume determination: The sample solutions are respectively determined to the total weight of each prescription;
[0109] (3) Shearing: speed 2500 rpm, time 30 min;
[0110] (4) Degassing: Transfer the sample solution to a degassing bottle and degas by vacuuming until no bubbles are generated;
[0111] (5) Filling and pre-freezing: Use a pipette to inject the sample, with the injection amount of 0.4 g / tablet, and place the injected aluminum-plastic blister in a -60°C low-temperature storage box for pre-freezing;
[0112] (6) Freeze drying: Set the initial freeze drying temperature to -30°C and place the pre-frozen blister plate into the freeze drying chamber. The specific freeze drying setting parameters are as follows:
[0113] Cold trap temperature: -40℃~-60℃; vacuum control: 20~30pa;
[0114] Plate temperature: from -30℃ to -5℃, 25 minutes; maintain -5℃, 120 minutes;
[0115] From -5℃ to 25℃, 30 minutes.
[0116] name effect Prescription 2 Prescription 3 API Active ingredients 0.693g 0.693g Pullulan Adhesives 0.8g 0.8g Maltodextrin Scaffold Agent 5g 5g Glycine Scaffold Agent / / Mannitol Scaffold Agent / / Gum Arabic Suspending Agents / / Sodium alginate Suspending Agents 720mg / Xanthan gum Suspending Agents / 720mg Sucralose Flavoring agents 100mg 100mg Mint flavor Flavoring agents 40mg 40mg Wahaha purified water Solvents / / Total weight / 40.0g 40.0g
[0117] 1.2 Experimental Results
[0118] prescription Prescription 2 Prescription 3 Intermediate solution Easy to settle There are clumps Appearance 4+ 3+ Sticky wall 5+ 2+ Disintegration 5+ 5+
[0119] Comparative Example 2 Investigating the Effect of Glycine or Mannitol as a Scaffold Supporting Agent on Freeze-dried Orally Disintegrating Tablets of Amlodipine Besylate When the Suspending Agent is Gum Arabic
[0120] 2.1 Preparation method of amlodipine besylate freeze-dried orally disintegrating tablets
[0121] The amlodipine besylate freeze-dried orally disintegrating tablets were prepared according to the prescription in the following table.
[0122] (1) Weigh the prescribed amount of glycine or mannitol, pullulan, gum arabic, and API (grinded to control the particle size D90 to 10 μm) in a 100 ml shear cup, dry mix, first add 20% of the prescribed amount of purified water and stir, then gradually add to 80% of the prescribed amount of purified water, bathe in 40°C water for 30 min, cool to room temperature, add the prescribed amount of sucralose and mint flavor, and stir to dissolve;
[0123] (2) Volume determination: The sample solutions are respectively determined to the total weight of each prescription;
[0124] (3) Shearing: speed 2500 rpm, time 30 min;
[0125] (4) Degassing: Transfer the sample solution to a degassing bottle and degas by vacuuming until no bubbles are generated;
[0126] (5) Filling and pre-freezing: Use a pipette to inject the sample, with the injection amount of 0.4 g / tablet, and place the injected aluminum-plastic blister in a -60°C low-temperature storage box for pre-freezing;
[0127] (6) Freeze drying: Set the initial freeze drying temperature to -30°C and place the pre-frozen blister plate into the freeze drying chamber. The specific freeze drying setting parameters are as follows:
[0128] Cold trap temperature: -40℃~-60℃; vacuum control: 20~30pa;
[0129] Plate temperature: from -30℃ to -5℃, 25 minutes; maintain -5℃, 120 minutes;
[0130] From -5℃ to 25℃, 30 minutes.
[0131] name effect Prescription 4 Prescription 5 API Active ingredients 0.693g 0.693g Pullulan Adhesives 0.8g 0.8g Maltodextrin Scaffold Agent / / Glycine Scaffold Agent 5g / Mannitol Scaffold Agent / 5g Gum Arabic Suspending Agents 720mg 720mg Sodium alginate Suspending Agents / / Xanthan gum Suspending Agents / / Sucralose Flavoring agents 100mg 100mg Mint flavor Flavoring agents 40mg 40mg Wahaha purified water Solvents / / Total weight / 40.0g 40.0g
[0132] 2.2 Experimental Results
[0133] prescription Prescription 4 Prescription 5 Intermediate solution 5+ 5+ Appearance 2+ 3+ Sticky wall 2+ 2+ Disintegration 5+ 5+
[0134] By comparing Example 1 and Comparative Example 1, it can be seen that when sodium alginate is used as a suspending agent, the intermediate solution is easy to settle and the tablet appearance is general; when xanthan gum is used as a suspending agent, the intermediate solution has lumps and the tablet appearance is poor, so gum arabic is selected as a suspending agent. By comparing Example 1 and Comparative Example 2, it can be seen that when glycine or mannitol is used as a skeleton support agent, the tablet has a more serious wall sticking phenomenon and the tablet appearance is poor, so maltodextrin is selected as a skeleton support agent. By comparing Example 1 with Comparative Examples 1-2 as a whole, it can be found that when maltodextrin is used as a skeleton support agent and gum arabic is used as a suspending agent, the compounded prescription of the two can greatly improve the problem of tablet agglomeration caused by the poor stability of the raw material amlodipine besylate and easy moisture absorption when wet, while overcoming the problems of poor tablet formability, wall sticking and poor appearance.
Claims
1. A freeze-dried orally disintegrating tablet, It is characterized in that The freeze-dried orally disintegrating tablets contain active pharmaceutical ingredients, adhesives, skeleton support agents and suspending agents, wherein the skeleton support agent is maltodextrin, and the suspending agent is gum arabic; the active pharmaceutical ingredient is amlodipine besylate; the adhesive is pullulan; the freeze-dried orally disintegrating tablets contain 0.01 to 2.0 parts of amlodipine besylate by weight; the freeze-dried orally disintegrating tablets contain 0.1 to 2.0 parts of pullulan by weight; the freeze-dried orally disintegrating tablets contain 1.0 to 10.0 parts of maltodextrin by weight; and the freeze-dried orally disintegrating tablets contain 0.01 to 2.0 parts of gum arabic by weight.
2. A freeze-dried orally disintegrating tablet according to claim 1, It is characterized in that The freeze-dried orally disintegrating tablet further comprises a sweetener or an edible flavor or a mixture of a sweetener and an edible flavor.
3. A freeze-dried orally disintegrating tablet according to claim 1, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.1 to 1.0 parts of amlodipine besylate by weight.
4. A freeze-dried orally disintegrating tablet according to claim 3, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.693 parts of amlodipine besylate by weight.
5. A freeze-dried orally disintegrating tablet according to claim 1 or 2, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.1 to 1.0 parts of pullulan by weight.
6. The freeze-dried orally disintegrating tablet according to claim 5, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.8 parts of pullulan by weight.
7. A freeze-dried orally disintegrating tablet according to claim 1 or 2, It is characterized in that The freeze-dried orally disintegrating tablet contains 2.0 to 8.0 parts of maltodextrin by weight.
8. The freeze-dried orally disintegrating tablet according to claim 7, It is characterized in that The freeze-dried orally disintegrating tablet contains 5.0 parts of maltodextrin by weight.
9. The freeze-dried orally disintegrating tablet of amlodipine besylate according to claim 1 or 2, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.01 to 1.0 parts of gum arabic by weight.
10. The freeze-dried orally disintegrating tablet of amlodipine besylate according to claim 9, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.72 parts of gum arabic by weight.
11. The freeze-dried orally disintegrating tablet according to claim 2, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.01 to 1.0 parts of sweetener by weight.
12. The freeze-dried orally disintegrating tablet according to claim 2, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.01 to 0.5 parts of sweetener by weight.
13. The freeze-dried orally disintegrating tablet according to claim 2, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.1 parts of sweetener by weight, wherein the sweetener is selected from: one or a combination of two or more of sucralose, aspartame, saccharin sodium, neotame, acesulfame potassium, aspartame and sucrose.
14. The freeze-dried orally disintegrating tablet according to claim 2, It is characterized in that The sweetener is sucralose.
15. The freeze-dried orally disintegrating tablet according to claim 2, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.01 to 1.0 parts of edible flavor by weight.
16. The freeze-dried orally disintegrating tablet according to claim 2, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.01 to 0.1 parts of edible flavor by weight.
17. The freeze-dried orally disintegrating tablet according to claim 2, It is characterized in that The freeze-dried orally disintegrating tablet contains 0.04 parts of edible flavor by weight, wherein the edible flavor is selected from: mint flavor, sweet orange flavor, pineapple flavor, strawberry flavor, or a combination of two or more thereof.
18. The freeze-dried orally disintegrating tablet according to claim 2, It is characterized in that The edible flavor is mint flavor.
19. The freeze-dried orally disintegrating tablet according to claim 1, It is characterized in that The preparation method of the freeze-dried orally disintegrating tablet comprises: (1) Weigh amlodipine besylate, pullulan, maltodextrin and gum arabic, add water, and stir to obtain a lyophilized solution; (2) degassing the lyophilized solution in step (1); (3) injecting the degassed freeze-dried solution in step (2) into a mold; (4) freeze-drying the mold filled with the freeze-dried solution in step (3).
20. The freeze-dried orally disintegrating tablet according to claim 2, It is characterized in that The preparation method of the freeze-dried orally disintegrating tablet comprises: (1) Weigh amlodipine besylate, pullulan, maltodextrin and gum arabic, add water, stir, heat, cool to room temperature, add sweetener and edible flavor, stir, and obtain a lyophilized solution; (2) degassing the lyophilized solution in step (1); (3) injecting the degassed freeze-dried solution in step (2) into a mold; (4) freeze-drying the mold filled with the freeze-dried solution in step (3).
